SUPHA
SUPHA PHARMACHEM financials
- Market cap
- ₹37 Cr
Quarterly results
Q2 FY26: revenue up 342.8%, net profit up 384.3% against the same quarter last year.
| Line item | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,834 | 1,408 | 78 | 25 | 38 −98% | 264 −81% | 113 +46% | 111 +343% |
| EBITDA | 55 | -35 | 0 | 4 | -5 −110% | -0 +99% | 2 +379% | 7 +65% |
| Net profit | 46 | -54 | 2 | 2 | 1 −98% | -2 +96% | 5 +184% | 9 +384% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −81.3% 1Y
1Y: ₹1.44 on 9 Sept 2025 → ₹0.27. High ₹1.59 (4 Nov 2025), low ₹0.26 (16 Jun 2026).
Financials, as filed
Revenue fell 29.2% a year over 2 years, FY23 to FY25. Operating margin narrowed to 0.6%.
| Year ending | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | ₹1.1k Cr | ₹3.3k Cr | ₹527 Cr |
| Operating profit | ₹12 Cr | ₹25 Cr | ₹3 Cr |
| Operating margin | 1.2% | 0.7% | 0.6% |
| Interest | ₹-0 Cr | ₹7 Cr | ₹2 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹9 Cr | ₹-4 Cr | ₹12 Cr |
| Net margin | 0.8% | -0.1% | 2.3% |
| Cash from operations | — | — | ₹-1.1k Cr |
| Free cash flow | — | — | ₹-1.1k Cr |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY25 |
|---|---|
| Equity capital | ₹88 Cr |
| Reserves | ₹17 Cr |
| Borrowings | ₹1.1k Cr |
| Other liabilities | ₹430 Cr |
| Total liabilities | ₹1.6k Cr |
| Fixed assets | ₹6 Cr |
| Capital work in progress | ₹0 Cr |
| Investments | ₹0 Cr |
| Other assets | ₹1.6k Cr |
| Total assets | ₹1.6k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Dec 2025
Since Dec 2024, the public trimmed −1.72 pp while FIIs added +1.70 pp. The shareholder count grew 51% to 1,11,269.
- Promoters
- 1.1%
- FIIs
- 1.7%
- Public
- 97.2%
Since Dec 2024
- Public −1.72 pp
- FIIs +1.70 pp
- Promoters +0.02 pp
How it drifted, 12 quarters
Over this window the public fell from 98.9% to 97.2% — −1.7 pp.
Ownership split by quarter, oldest first. Mar '23: Promoters 1.1%, Public 98.9%.Jun '23: Promoters 1.1%, FIIs 0.0%, Public 98.8%.Sep '23: Promoters 1.1%, FIIs 0.1%, Public 98.8%.Dec '23: Promoters 1.1%, FIIs 0.0%, Public 98.9%.Mar '24: Promoters 1.1%, FIIs 0.0%, Public 98.8%.Jun '24: Promoters 1.1%, Public 98.9%.Sep '24: Promoters 1.1%, Public 98.9%.Dec '24: Promoters 1.1%, Public 98.9%.Mar '25: Promoters 1.1%, Public 98.9%.Jun '25: Promoters 1.1%, Public 98.9%.Sep '25: Promoters 1.1%, Public 98.9%.Dec '25: Promoters 1.1%, FIIs 1.7%, Public 97.2%.
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Manju Devi newly disclosed 2.46% held
- Zeta Global Funds (Oeic) Pcc Limited-Zeta Series B Fund Pc FPI fund newly disclosed 1.70% held
- Randeep Singh . newly disclosed 1.22% held
- Kamal Asnani +1.08 pp 2.19% held
- Krishna Kumar Goyal newly disclosed 1.08% held
- L7 Hitech Private Limited +0.58 pp 2.34% held
- Comfort Capital Private Limited +0.15 pp 1.65% held
The same filing shows 0 holders trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Dec 2025 filing
Every holder of SUPHA PHARMACHEM LIMITED above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Uppinangady Sudhindra Nayak | 3.20% | unchanged |
| Manju Devi | 2.46% | newly disclosed |
| L7 Hitech Private Limited | 2.34% | +0.58 pp |
| Kamal Asnani | 2.19% | +1.08 pp |
| Zeta Global Funds (Oeic) Pcc Limited-Zeta Series B Fund Pc FPI fund | 1.70% | newly disclosed |
| Comfort Capital Private Limited | 1.65% | +0.15 pp |
| Randeep Singh . | 1.22% | newly disclosed |
| Siddharth Chimanlal Shah | 1.13% | unchanged |
| Krishna Kumar Goyal | 1.08% | newly disclosed |
| Vignesh Prabhu Hejamadi | 1.06% | unchanged |
| Sahay Investment Services | — | off the list |
| Arya Worldwide | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse SUPHA PHARMACHEM LIMITED
Guides on how to read this kind of business and the numbers that matter.